1 |
FitzGerald, G.A. (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879-890
DOI
ScienceOn
|
2 |
Ishii, T., Itoh, K., Ruiz, E., Leake, D.S., Unoki, H., Yamamoto, M., and Mann, G.E. (2004). Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 94, 609-616
DOI
ScienceOn
|
3 |
Kumagai, T., Kawamoto, Y., Nakamura, Y., Hatayama, I., Satoh, K., Osawa, T., and Uchida, K. (2000). 4-Hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem. Biophys. Res. Commun. 273, 437-771
DOI
ScienceOn
|
4 |
Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg. Cell 93, 229-240
DOI
ScienceOn
|
5 |
Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. (1989). Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924
DOI
ScienceOn
|
6 |
Suc, I., Meilhac, O., Lajoie-Mazenc, I., Vandaele, J., Jurgens, G., Salvayre, R., and Negre-Salvayre, A. (1998). Activation of EGF receptor by oxidized LDL. FASEB J. 12, 665-671
DOI
|
7 |
Ziouzenkova, O., Asatryan, L., Akmal, M., Tetta, C., Wratten, M.-L., Heinecke, J., and Sevanian, A. (1999). Cross-linking between low density lipoprotein apoB and hemoglobin mediates conversion to electronegative LDL- during the ex-vivo blood circulation. J. Biol. Chem. 274, 18916-18924
DOI
|
8 |
Kanayama, M., Yamaguchi, S., Shibata, T., Shibata, N., Kobayashi, M., Nagai, R., Arai, H., Takahashi, K., and Uchida, K. (2007). Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4- hydroxy-2-nonenal. J. Biol. Chem. 282, 24166-24174
DOI
ScienceOn
|
9 |
Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P.J., Shan, L., Gugiu, B., Fox, P.L., et al. (2002). Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277, 38503-38516
DOI
ScienceOn
|
10 |
Uchida, K. (2003). 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42, 318-343
DOI
ScienceOn
|
11 |
Quinn, M.T., Parthasarathy, S., Fong, L.G., and Steinberg, D. (1987). Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 84, 2995-2998
|
12 |
Kumagai, T., Nakamura, Y., Osawa, T., and Uchida, K. (2002). Role of p38 mitogen-activated protein kinase in the 4- hydroxy-2-nonenal-induced cyclooxygenase-2 expression. Arch. Biochem. Biophys. 397, 240-245
DOI
ScienceOn
|
13 |
Sevanian, A., Hwang, J., Hodis, H.N., Cazzolato, G., Avogaro, P., and Bittolo-Bon, G. (1996). Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler. Thromb. 16, 784-793
DOI
ScienceOn
|
14 |
Gimbrone, M.A. Jr., Topper, J.N., Nagel, T., Anderson, K.R., and Garcia-Cardena, G. (2000). Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N.Y. Acad. Sci. 902, 230-239
DOI
|
15 |
Huang, D., Jang, B.C., Yu, G., and Boudreau, M. (1997). Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF- signaling pathways in macrophages. Biochem. Pharmacol. 54, 87-96
DOI
ScienceOn
|
16 |
Sevanian, A., Asatryan, L., and Ziouzenkova, O. (1999). Low density lipoprotein (LDL) modification: basic concepts and relationship to atherosclerosis. Blood Purif. 17, 66-78
DOI
ScienceOn
|
17 |
Glass, C.K., and Witztum, J.L. (2001). Atherosclerosis. The road ahead. Cell 104, 503-516
DOI
ScienceOn
|
18 |
Steinberg, D. (1995). Role of oxidized LDL and antioxidants in atherosclerosis. Adv. Exp. Med. Biol. 369, 39-48
|
19 |
Koki, A., Khan, N.K., Woerner, B.M., Dannenberg, A.J., Olson, L., Seibert, K., Edwards, D., Hardy, M., Isakson, P., and Masferrer, J.L. (2002). Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 507, 177-184
|
20 |
Reddy, S.T., Wadleigh D.J., and Herschman, H.R. (2000). Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J. Biol. Chem. 275, 3107-3113
DOI
ScienceOn
|
21 |
Smith, W.L., and Langenbach, R. (2001). Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107, 1491-1495
DOI
ScienceOn
|
22 |
Kumagai, T., Matsukawa, N., Kaneko, Y., Kusumi, Y., Mitsumata, M., and Uchida, K. (2004). A lipid peroxidationderived inflammatory mediator: Identification of 4-hydroxy- 2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J. Biol. Chem. 279, 48389-48396
DOI
ScienceOn
|
23 |
FitzGerald, G.A., Austin, S., Egan, K., Cheng, Y., and Pratico, D. (2000). Cyclo-oxygenase products and atherothrombosis. Ann. Med. 32, 21-26
|
24 |
Sevanian, A., Bittolo-Bon, G., Cazzolato, G., Hodis, H., Hwang, J., Zamburlini, A., Maiorino, M., and Ursini, F. (1997). LDLis a lipid hydroperoxide-enriched circulating lipoprotein. J. Lipid Res. 38, 419-428
|